2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152240
    PD-1/PD-L1-IN-29
    		Inhibitor 99.96%
    PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity.
    PD-1/PD-L1-IN-29
  • HY-P9996
    Reozalimab
    		Inhibitor 99.90%
    Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research.
    Reozalimab
  • HY-W771599
    ASC-69
    		Inhibitor 99.63%
    ASC-69 (APY69)is a potent and promising?PD-1/PD-L1 small-molecule inhibitor.
    ASC-69
  • HY-P1812
    AUNP-12
    		Antagonist 99.31%
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
    AUNP-12
  • HY-132202
    PD-1/PD-L1-IN-10
    		Inhibitor 99.61%
    PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
    PD-1/PD-L1-IN-10
  • HY-P99544
    Tagitanlimab
    		Inhibitor ≥99.0%
    Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC).
    Tagitanlimab
  • HY-P4072A
    (D)-PPA 1 TFA
    		Inhibitor 99.84%
    (D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.
    (D)-PPA 1 TFA
  • HY-147311
    NSC622608
    		Inhibitor 99.53%
    NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.
    NSC622608
  • HY-P99618
    Fidasimtamab
    		Inhibitor
    Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity.
    Fidasimtamab
  • HY-150879
    BMS-37
    		Inhibitor 98.01%
    BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor. BMS-37 can be used as PD-L1 ligand to synthesize PROTAC molecules.
    BMS-37
  • HY-102011A
    BMS-1166 hydrochloride
    		Inhibitor 99.95%
    BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
    BMS-1166 hydrochloride
  • HY-145239
    PD-1/PD-L1-IN-13
    		Inhibitor 99.52%
    PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8+ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model.
    PD-1/PD-L1-IN-13
  • HY-P99489
    Budigalimab
    		Inhibitor 99.79%
    Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors.
    Budigalimab
  • HY-P99944
    SHR-1701
    		99.77%
    SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research.
    SHR-1701
  • HY-131347
    PD-1/PD-L1-IN-NP19
    		Inhibitor 98.25%
    PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects.
    PD-1/PD-L1-IN-NP19
  • HY-P99895
    Rulonilimab
    		Inhibitor
    Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity.
    Rulonilimab
  • HY-134886
    PD-1-IN-24
    		Inhibitor 98.12%
    PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.
    PD-1-IN-24
  • HY-P99109
    Zimberelimab
    		Inhibitor 99.90%
    Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma.
    Zimberelimab
  • HY-P3342
    [D-Leu-4]-OB3
    		Inhibitor 99.31%
    [D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes.
    [D-Leu-4]-OB3
  • HY-P99540
    Tuvonralimab
    		Inhibitor 99.14%
    Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab.
    Tuvonralimab
Cat. No. Product Name / Synonyms Application Reactivity